AnHeart Therapeutics

Acquired

New York, China · Founded 2018 · $75.6M raised

Headquarters
New York
Employees
51–200
Founded
2018
Business Model
B2B
Total Funding
$75.6M
Last Round
$61.0M Series BDec 2021
Rounds
3
Acquired by
Nuvation Bio Inc.Mar 2024

About

AnHeart Therapeutics is a clinical-stage global biopharmaceutical company founded in 2018 and headquartered in New York City, with significant operations in China. The company focused on developing precision oncology therapeutics, most notably taletrectinib, a next-generation ROS1/NTRK inhibitor targeting ROS1 fusion-positive non-small cell lung cancer (NSCLC) and other solid tumors. AnHeart built a broad pipeline addressing underserved cancer subtypes and was acquired by Nuvation Bio in April 2024 in an all-stock transaction, transforming Nuvation into a late-stage global oncology company with commercial-stage potential.

Summary

AnHeart Therapeutics is a Biotech company based in New York, China, founded in 2018. It has raised $75.6M in total across 3 rounds, most recently a $61.0M Series B round in Dec 2021. Investors include Decheng Capital, Vertex Ventures China and Cenova Capital.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

AcquisitionMar 2024

Sign up to see all 4 rounds

Series A through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

AnHeart Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/anheart-therapeutics"><img src="https://indexed.vc/api/badge/company/anheart-therapeutics" alt="AnHeart Therapeutics on Indexed.vc" width="260" height="76" /></a>